|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ACAT1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:58,166,990...58,195,884
Ensembl chr 8:58,166,990...58,195,884
|
|
G |
Acsf2 |
acyl-CoA synthetase family member 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ACSF2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:82,284,719...82,326,771
Ensembl chr10:82,284,720...82,326,771
|
|
G |
Acss2 |
acyl-CoA synthetase short-chain family member 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ACSS2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:151,032,925...151,075,856
Ensembl chr 3:151,032,952...151,075,856
|
|
G |
Adgrg1 |
adhesion G protein-coupled receptor G1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ADGRG1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:10,423,534...10,460,674
Ensembl chr19:10,423,501...10,460,674
|
|
G |
Adora2b |
adenosine A2B receptor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ADORA2B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:48,569,563...48,586,366
Ensembl chr10:48,569,555...48,586,365
|
|
G |
Ahnak2 |
AHNAK nucleoprotein 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AHNAK2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:137,335,273...137,380,219
|
|
G |
Akap12 |
A-kinase anchoring protein 12 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of AKAP12 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:40,816,130...40,906,582
Ensembl chr 1:40,816,107...40,906,581
|
|
G |
Aldh1l2 |
aldehyde dehydrogenase 1 family, member L2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ALDH1L2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:26,375,866...26,425,838
Ensembl chr 7:26,375,866...26,425,108
|
|
G |
Aldh7a1 |
aldehyde dehydrogenase 7 family, member A1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ALDH7A1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:51,619,007...51,651,267
Ensembl chr18:51,619,007...51,651,267
|
|
G |
Aldh9a1 |
aldehyde dehydrogenase 9 family, member A1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ALDH9A1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:85,580,828...85,597,497
Ensembl chr13:85,580,828...85,597,493
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ALDOC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:65,586,504...65,590,093
Ensembl chr10:65,586,504...65,590,126
|
|
G |
Angptl4 |
angiopoietin-like 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:18,627,814...18,634,043
Ensembl chr 7:18,627,808...18,634,079
|
|
G |
Anxa11 |
annexin A11 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ANXA11 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:3,867,193...3,912,043
Ensembl chr16:3,867,208...3,912,148
|
|
G |
Anxa2 |
annexin A2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ANXA2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:75,687,134...75,723,589
Ensembl chr 8:75,687,100...75,723,594
|
|
G |
Anxa8 |
annexin A8 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ANXA8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:10,417,174...10,432,388
Ensembl chr16:10,417,185...10,432,393
|
|
G |
Aox1 |
aldehyde oxidase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AOX1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:64,929,682...65,007,872
Ensembl chr 9:64,929,721...65,007,870
|
|
G |
Ap1b1 |
adaptor related protein complex 1 subunit beta 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AP1B1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:85,230,652...85,281,806
Ensembl chr14:85,230,648...85,281,803
|
|
G |
Ap1s2 |
adaptor related protein complex 1 subunit sigma 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AP1S2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:32,329,883...32,376,301
Ensembl chr X:32,329,598...32,355,307
|
|
G |
Ap2s1 |
adaptor related protein complex 2 subunit sigma 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AP2S1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:78,671,238...78,682,847
Ensembl chr 1:78,671,121...78,682,871
|
|
G |
Ap3d1 |
adaptor related protein complex 3 subunit delta 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of AP3D1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:11,838,639...11,873,992
Ensembl chr 7:11,838,639...11,873,984
|
|
G |
Apbb3 |
amyloid beta precursor protein binding family B member 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of APBB3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:29,497,865...29,504,995
Ensembl chr18:29,497,863...29,504,995
|
|
G |
Arap3 |
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ARAP3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:31,112,083...31,138,142
Ensembl chr18:31,112,623...31,136,200
|
|
G |
Arhgef16 |
Rho guanine nucleotide exchange factor 16 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ARHGEF16 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:171,626,450...171,649,124
Ensembl chr 5:171,624,796...171,648,563
|
|
G |
Arid5b |
AT-rich interaction domain 5B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ARID5B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:21,713,900...21,881,193
Ensembl chr20:21,564,975...21,880,715
|
|
G |
Arl4a |
ADP-ribosylation factor like GTPase 4A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ARL4A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:59,945,926...59,950,586
Ensembl chr 6:59,948,577...59,950,586
|
|
G |
Arl5a |
ADP-ribosylation factor like GTPase 5A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ARL5A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:37,922,544...37,947,434
Ensembl chr 3:37,924,793...37,947,283
|
|
G |
Atp5mg |
ATP synthase membrane subunit g |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ATP5L mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:49,220,441...49,227,273
Ensembl chr 8:49,220,443...49,227,273
|
|
G |
Atp5pf |
ATP synthase peripheral stalk subunit F6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ATP5J mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:24,286,806...24,294,419
Ensembl chr11:24,286,787...24,294,179
|
|
G |
Atp6v0b |
ATPase H+ transporting V0 subunit B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ATP6V0B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:136,718,352...136,719,868
Ensembl chr 5:136,718,352...136,721,379
|
|
G |
Atp6v0e1 |
ATPase H+ transporting V0 subunit e1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ATP6V0E1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:16,769,857...16,792,930
Ensembl chr10:16,769,666...16,792,909
|
|
G |
Atp8b2 |
ATPase phospholipid transporting 8B2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ATP8B2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:189,285,961...189,306,947
Ensembl chr 2:189,285,953...189,307,108
|
|
G |
Atp9a |
ATPase phospholipid transporting 9A (putative) |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ATP9A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:165,405,588...165,511,104
Ensembl chr 3:165,412,803...165,477,771
|
|
G |
B4galt5 |
beta-1,4-galactosyltransferase 5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of B4GALT5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:164,039,731...164,055,561
Ensembl chr 3:164,039,731...164,095,878
|
|
G |
Bcar3 |
BCAR3 adaptor protein, NSP family member |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BCAR3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:226,563,050...226,679,449
Ensembl chr 2:226,563,050...226,679,438
|
|
G |
Bckdk |
branched chain ketoacid dehydrogenase kinase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BCKDK mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:199,351,628...199,356,299
Ensembl chr 1:199,351,628...199,356,881
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BHLHE40 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:140,703,619...140,709,319
Ensembl chr 4:140,703,619...140,709,319
|
|
G |
Bik |
BCL2-interacting killer |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of BIK mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:124,390,924...124,410,449
Ensembl chr 7:124,391,432...124,410,447
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BNIP3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
|
|
G |
Cacybp |
calcyclin binding protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CACYBP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:77,948,771...77,959,089
Ensembl chr13:77,948,771...77,959,110
|
|
G |
Card10 |
caspase recruitment domain family, member 10 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CARD10 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:119,998,639...120,028,632
Ensembl chr 7:119,999,472...120,027,026
|
|
G |
Casp2 |
caspase 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CASP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:71,652,358...71,670,228
Ensembl chr 4:71,652,354...71,670,239
|
|
G |
Cav2 |
caveolin 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CAV2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:44,573,264...44,580,640
Ensembl chr 4:44,573,264...44,580,638
|
|
G |
Ccdc12 |
coiled-coil domain containing 12 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCDC12 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:118,925,682...118,977,038
Ensembl chr 8:118,926,478...118,977,051
|
|
G |
Ccdc92 |
coiled-coil domain containing 92 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCDC92 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:37,210,735...37,237,848
Ensembl chr12:37,211,316...37,237,848
|
|
G |
Ccdc93 |
coiled-coil domain containing 93 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCDC93 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:37,400,455...37,473,973
Ensembl chr13:37,400,476...37,468,840
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCN2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CCND2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
|
|
G |
Cd24 |
CD24 molecule |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CD24 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:48,335,540...48,340,847
Ensembl chr20:48,335,540...48,340,846
|
|
G |
Cd63 |
Cd63 molecule |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CD63 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:3,320,250...3,335,583
Ensembl chr 7:3,320,103...3,335,582
|
|
G |
Cd99l2 |
CD99 molecule-like 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CD99L2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr15:5,265,257...5,311,232
Ensembl chr15:5,265,307...5,311,233 Ensembl chr15:5,265,307...5,311,233
|
|
G |
Cdc20 |
cell division cycle 20 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CDC20 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:137,260,728...137,264,931
Ensembl chr 5:137,260,739...137,265,015
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which affects the expression of CDH1 mRNA; [[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CDH1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Cdh3 |
cadherin 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CDH3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:38,668,957...38,719,801
Ensembl chr19:38,669,230...38,719,677
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CDKN1A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cenpa |
centromere protein A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CENPA mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:27,072,259...27,080,863
Ensembl chr 6:27,072,166...27,080,856
|
|
G |
Cenpf |
centromere protein F |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CENPF mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:108,132,499...108,178,609
Ensembl chr13:108,132,499...108,178,609
|
|
G |
Cep192 |
centrosomal protein 192 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CEP192 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:63,572,084...63,656,302
Ensembl chr18:63,524,452...63,656,286
|
|
G |
Cfap251 |
cilia and flagella associated protein 251 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CFAP251 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:38,708,915...38,781,598
Ensembl chr12:38,709,595...38,782,010
|
|
G |
Chd9 |
chromodomain helicase DNA binding protein 9 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CHD9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:17,364,969...17,517,757
Ensembl chr19:17,366,828...17,494,585
|
|
G |
Chrna2 |
cholinergic receptor nicotinic alpha 2 subunit |
multiple interactions |
ISO |
isobutyl alcohol affects the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]] |
CTD |
PMID:11821649 |
|
NCBI chr15:42,808,897...42,825,179
Ensembl chr15:42,808,897...42,825,179
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
ISO |
isobutyl alcohol affects the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]] |
CTD |
PMID:11821649 |
|
NCBI chr 8:59,610,489...59,629,073
Ensembl chr 8:59,609,693...59,629,133
|
|
G |
Chtop |
chromatin target of PRMT1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CHTOP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:189,887,850...189,900,079
Ensembl chr 2:189,887,857...189,899,325
|
|
G |
Cited4 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CITED4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:139,597,731...139,598,622
Ensembl chr 5:139,597,731...139,598,622
|
|
G |
Cklf |
chemokine-like factor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CKLF mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:903,609...914,880
Ensembl chr19:906,411...914,880
|
|
G |
Cks2 |
CDC28 protein kinase regulatory subunit 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CKS2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:13,587,664...13,593,423
Ensembl chr17:13,587,665...13,593,423
|
|
G |
Clcn6 |
chloride voltage-gated channel 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CLCN6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:164,811,815...164,844,554
Ensembl chr 5:164,811,816...164,844,586
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CLDN1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:77,815,216...77,830,373
Ensembl chr11:77,815,181...77,830,416
|
|
G |
Cnn2 |
calponin 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CNN2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:12,782,459...12,787,977
Ensembl chr 7:12,782,491...12,787,750
|
|
G |
Cnpy4 |
canopy FGF signaling regulator 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CNPY4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:19,329,027...19,335,126
Ensembl chr12:19,328,957...19,335,119
|
|
G |
Coa3 |
cytochrome C oxidase assembly factor 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCDC56 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:89,198,750...89,199,731
Ensembl chr10:89,198,749...89,199,736
|
|
G |
Commd1 |
copper metabolism domain containing 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of COMMD1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:107,664,321...107,759,974
Ensembl chr14:107,664,255...107,760,191
|
|
G |
Coq3 |
coenzyme Q3 methyltransferase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of COQ3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:36,024,673...36,056,664
Ensembl chr 5:36,024,649...36,056,669
|
|
G |
Coq5 |
coenzyme Q5, methyltransferase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of COQ5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:47,078,753...47,095,438
Ensembl chr12:47,078,753...47,095,438
|
|
G |
Cotl1 |
coactosin-like F-actin binding protein 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of COTL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:52,465,074...52,499,433
Ensembl chr19:52,465,087...52,499,433
|
|
G |
Cox16 |
cytochrome c oxidase assembly factor COX16 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of COX16 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:105,195,387...105,214,366
Ensembl chr 6:105,201,395...105,214,329
|
|
G |
Cox7c |
cytochrome c oxidase subunit 7C |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of COX7C mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:14,699,878...14,701,903
Ensembl chr 2:14,699,882...14,701,903
|
|
G |
Cpa4 |
carboxypeptidase A4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CPA4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:57,883,849...57,907,826
Ensembl chr 4:57,883,849...57,907,826
|
|
G |
Cpd |
carboxypeptidase D |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CPD mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:63,325,764...63,389,811
Ensembl chr10:63,325,199...63,389,817
|
|
G |
Creb3l2 |
cAMP responsive element binding protein 3-like 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CREB3L2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:64,869,285...64,981,519
Ensembl chr 4:64,869,026...64,981,384
|
|
G |
Cript |
CXXC repeat containing interactor of PDZ3 domain |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CRIPT mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:10,594,147...10,602,103
Ensembl chr 6:10,594,122...10,602,085
|
|
G |
Crispld2 |
cysteine-rich secretory protein LCCL domain containing 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CRISPLD2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:52,647,038...52,705,118
Ensembl chr19:52,647,070...52,705,131
|
|
G |
Csk |
C-terminal Src kinase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CSK mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:62,405,714...62,424,707
Ensembl chr 8:62,405,715...62,424,303
|
|
G |
Csnk1e |
casein kinase 1, epsilon |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CSNK1E mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:120,651,976...120,675,559
Ensembl chr 7:120,651,881...120,672,359
|
|
G |
Cul1 |
cullin 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CUL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:77,211,814...77,283,369
Ensembl chr 4:77,211,692...77,280,250
|
|
G |
Cuta |
cutA divalent cation tolerance homolog |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CUTA mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:5,532,024...5,533,640
Ensembl chr20:5,532,024...5,533,620
|
|
G |
Cwc15 |
CWC15 spliceosome-associated protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CWC15 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:12,994,131...13,004,958
Ensembl chr 8:12,994,155...13,004,957
|
|
G |
Cxxc5 |
CXXC finger protein 5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CXXC5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:28,626,386...28,656,916
Ensembl chr18:28,653,592...28,656,937
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CYBA mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:55,249,634...55,257,824
Ensembl chr19:55,249,616...55,257,876
|
|
G |
Cygb |
cytoglobin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CYGB mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:105,618,325...105,628,091
Ensembl chr10:105,618,326...105,628,091
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CYP1A1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp4x1 |
cytochrome P450, family 4, subfamily x, polypeptide 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CYP4X1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:133,929,532...133,959,447
Ensembl chr 5:133,929,532...133,959,447
|
|
G |
Cysrt1 |
cysteine rich tail 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CYSRT1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:2,458,295...2,462,037
Ensembl chr 3:2,458,295...2,459,385
|
|
G |
Dapk3 |
death-associated protein kinase 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of DAPK3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:11,392,436...11,400,855
Ensembl chr 7:11,392,437...11,400,805
|
|
G |
Dbi |
diazepam binding inhibitor, acyl-CoA binding protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DBI mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:36,147,667...36,156,076
Ensembl chr13:36,117,119...36,174,908
|
|
G |
Dbt |
dihydrolipoamide branched chain transacylase E2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DBT mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:219,563,783...219,592,651
Ensembl chr 2:219,563,783...219,592,650
|
|
G |
Dcaf15 |
DDB1 and CUL4 associated factor 15 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of DCAF15 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:25,212,469...25,219,803
Ensembl chr19:25,212,661...25,220,010
|
|
G |
Dcbld2 |
discoidin, CUB and LCCL domain containing 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DCBLD2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:44,237,814...44,292,884
Ensembl chr11:44,241,111...44,292,884
|
|
G |
Dcp2 |
decapping mRNA 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DCP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:35,489,274...35,671,676
Ensembl chr18:35,489,274...35,672,291
|
|
G |
Dctn5 |
dynactin subunit 5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DCTN5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:192,088,709...192,105,421
Ensembl chr 1:192,088,672...192,105,429
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DDIT4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:29,509,283...29,511,382
Ensembl chr20:29,509,289...29,511,382
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of DDR1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:3,553,430...3,574,959
Ensembl chr20:3,552,929...3,575,780
|
|
G |
Decr2 |
2,4-dienoyl-CoA reductase 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DECR2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:15,451,850...15,460,227
Ensembl chr10:15,431,638...15,465,413
|
|
G |
Dennd1a |
DENN domain containing 1A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DENND1A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:22,061,120...22,501,502
Ensembl chr 3:22,058,400...22,500,765
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of DKK1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:248,952,896...248,956,579
Ensembl chr 1:248,895,738...248,898,607
|
|
G |
Dnaaf10 |
dynein axonemal assembly factor 10 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DNAAF10 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:100,373,129...100,394,143
Ensembl chr14:100,373,129...100,394,145
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DNAJA1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:57,028,467...57,039,378
Ensembl chr 5:57,028,467...57,039,378
|
|
G |
Dnajb6 |
DnaJ heat shock protein family (Hsp40) member B6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DNAJB6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:2,711,329...2,774,969
Ensembl chr 4:2,711,385...2,774,890
|
|
G |
Dnase1l1 |
deoxyribonuclease 1-like 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DNASE1L1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:156,429,521...156,438,066
Ensembl chr X:156,429,585...156,438,066
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of EBP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:15,049,394...15,055,782
Ensembl chr X:15,049,462...15,055,781
|
|
G |
Eef1d |
eukaryotic translation elongation factor 1 delta |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of EEF1D mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:116,928,264...116,942,981
Ensembl chr 7:116,928,265...116,936,674
|
|
G |
Efnb1 |
ephrin B1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of EFNB1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:68,891,227...68,904,034
Ensembl chr X:68,891,227...68,904,038
|
|
G |
Efnb2 |
ephrin B2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of EFNB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:86,631,151...86,672,050
Ensembl chr16:86,631,064...86,675,049
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of EGR1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Elovl6 |
ELOVL fatty acid elongase 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ELOVL6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:234,187,490...234,296,124
Ensembl chr 2:234,189,105...234,296,145 Ensembl chr 2:234,189,105...234,296,145
|
|
G |
Elp6 |
elongator acetyltransferase complex subunit 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ELP6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:118,525,770...118,541,074
Ensembl chr 8:118,525,682...118,541,073
|
|
G |
Erh |
ERH, mRNA splicing and mitosis factor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ERH mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:104,280,390...104,290,905
Ensembl chr 6:104,280,408...104,290,579
|
|
G |
Exoc2 |
exocyst complex component 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of EXOC2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:34,665,810...34,842,266
Ensembl chr17:34,665,872...34,842,266
|
|
G |
Exosc2 |
exosome component 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of EXOSC2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:10,151,734...10,161,997
Ensembl chr 3:10,151,284...10,161,989
|
|
G |
Ezr |
ezrin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of EZR mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:47,287,872...47,331,412
Ensembl chr 1:47,287,874...47,331,412
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of F2RL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:25,222,324...25,235,275
Ensembl chr 2:25,222,328...25,235,275
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of F3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fam217b |
family with sequence similarity 217, member B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FAM217B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:173,953,752...173,961,615
Ensembl chr 3:173,953,869...173,963,629
|
|
G |
Fam98a |
family with sequence similarity 98, member A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FAM98A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:21,051,327...21,065,986
Ensembl chr 6:21,051,327...21,065,986
|
|
G |
Fance |
FA complementation group E |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FANCE mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:7,888,927...7,906,142
Ensembl chr20:7,895,083...7,906,142
|
|
G |
Fancl |
FA complementation group L |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FANCL mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:110,675,306...110,740,880
Ensembl chr14:110,676,090...110,740,317
|
|
G |
Fbxo2 |
F-box protein 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FBXO2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:164,972,483...164,977,912
Ensembl chr 5:164,972,480...164,977,916
|
|
G |
Fbxw5 |
F-box and WD repeat domain containing 5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FBXW5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:2,726,705...2,731,213
Ensembl chr 3:2,727,254...2,731,212
|
|
G |
Fez1 |
fasciculation and elongation protein zeta 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FEZ1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:39,305,128...39,350,270
Ensembl chr 8:39,305,128...39,350,270
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FGFR3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:82,272,322...82,287,739
Ensembl chr14:82,273,070...82,287,706
|
|
G |
Fgl1 |
fibrinogen-like 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FGL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:54,153,086...54,188,120
Ensembl chr16:54,153,054...54,188,181
|
|
G |
Fnbp1 |
formin binding protein 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FNBP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:9,865,657...9,936,333
Ensembl chr 3:9,861,237...9,936,405
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FOS mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FOSL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:220,826,560...220,835,066
Ensembl chr 1:220,826,560...220,835,066
|
|
G |
Foxj2 |
forkhead box J2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FOXJ2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:155,653,446...155,679,815
Ensembl chr 4:155,653,718...155,679,793
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FOXO3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
|
|
G |
Fst |
follistatin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FST mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:46,537,589...46,544,813
Ensembl chr 2:46,538,700...46,544,457
|
|
G |
Ftsj1 |
FtsJ RNA 2'-O-methyltransferase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FTSJ1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:14,993,685...15,006,010
Ensembl chr X:14,994,016...15,002,074
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GADD45A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Galnt11 |
polypeptide N-acetylgalactosaminyltransferase 11 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GALNT11 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:6,297,255...6,330,765
Ensembl chr 4:6,297,258...6,330,765
|
|
G |
Gbp1 |
guanylate binding protein 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GBP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:248,343,334...248,423,402
Ensembl chr 2:248,398,917...248,409,570
|
|
G |
Gjb2 |
gap junction protein, beta 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GJB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr15:37,377,313...37,394,494
Ensembl chr15:37,377,316...37,383,277
|
|
G |
Gldc |
glycine decarboxylase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GLDC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:248,295,140...248,377,122
Ensembl chr 1:248,297,331...248,377,093
|
|
G |
Glipr2 |
GLI pathogenesis-related 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GLIPR2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:59,415,415...59,446,732
Ensembl chr 5:59,416,076...59,446,647
|
|
G |
Glis3 |
GLIS family zinc finger 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GLIS3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:246,380,816...246,564,385
Ensembl chr 1:246,380,889...246,785,360
|
|
G |
Glmp |
glycosylated lysosomal membrane protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GLMP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:187,697,528...187,701,118
Ensembl chr 2:187,697,523...187,701,118
|
|
G |
Glrx |
glutaredoxin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GLRX mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:2,606,032...2,615,944
Ensembl chr 2:2,605,996...2,615,944
|
|
G |
Gng10 |
G protein subunit gamma 10 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GNG10 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:76,182,100...76,189,014
Ensembl chr 5:76,182,121...76,189,013
|
|
G |
Gpc1 |
glypican 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GPC1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:99,998,275...100,026,818
Ensembl chr 9:99,998,275...100,026,818
|
|
G |
Gpd1l |
glycerol-3-phosphate dehydrogenase 1-like |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GPD1L mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:122,957,570...122,987,236
Ensembl chr 8:122,954,948...122,987,191
|
|
G |
Gpr137 |
G protein-coupled receptor 137 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GPR137 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:222,194,266...222,197,252
Ensembl chr 1:222,194,266...222,197,252
|
|
G |
Grpel1 |
GrpE-like 1, mitochondrial |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GRPEL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:79,458,951...79,464,782
Ensembl chr14:79,458,963...79,464,770
|
|
G |
Gtf2b |
general transcription factor IIB |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GTF2B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:248,709,433...248,727,741
Ensembl chr 2:248,715,281...248,727,741
|
|
G |
Gtf2f1 |
general transcription factor IIF subunit 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GTF2F1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:10,032,806...10,042,392
Ensembl chr 9:10,033,011...10,042,418
|
|
G |
Gtpbp4 |
GTP binding protein 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GTPBP4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:63,111,086...63,145,618
Ensembl chr17:63,110,254...63,145,577
|
|
G |
Gypc |
glycophorin C (Gerbich blood group) |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GYPC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:25,312,386...25,344,614
Ensembl chr18:25,312,387...25,344,614
|
|
G |
Hirip3 |
HIRA interacting protein 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HIRIP3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:198,298,138...198,301,164
Ensembl chr 1:198,298,138...198,301,161
|
|
G |
Hmgb3 |
high mobility group box 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HMGB3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:36,690,190...36,694,329
Ensembl chr17:36,690,249...36,694,325 Ensembl chr14:36,690,249...36,694,325
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HMGCR mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HMGCS1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:52,427,351...52,445,082
Ensembl chr 2:52,431,601...52,445,055
|
|
G |
Hnrnpa3 |
heterogeneous nuclear ribonucleoprotein A3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of HNRNPA3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:62,481,222...62,491,356
Ensembl chr 3:62,481,323...62,487,227
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HNRNPK mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:6,664,730...6,676,753
Ensembl chr17:6,665,659...6,676,654
|
|
G |
Hoxb2 |
homeobox B2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HOXB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:84,200,859...84,203,065
Ensembl chr10:84,200,880...84,202,688
|
|
G |
Hps6 |
HPS6, biogenesis of lysosomal organelles complex 2 subunit 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HPS6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:265,761,818...265,764,427
Ensembl chr 1:265,761,738...265,764,437
|
|
G |
Hsd17b8 |
hydroxysteroid (17-beta) dehydrogenase 8 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HSD17B8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:3,817,212...3,819,316
Ensembl chr20:3,817,179...3,819,235
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HSPA8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:44,989,401...44,993,261
Ensembl chr 8:44,990,014...44,993,179
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of HSPB1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of IL1B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il24 |
interleukin 24 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of IL24 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:47,618,451...47,623,849
Ensembl chr13:47,618,452...47,623,849
|
|
G |
Ino80c |
INO80 complex subunit C |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of INO80C mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:15,995,005...16,009,639
Ensembl chr18:15,995,000...16,009,710
|
|
G |
Insig1 |
insulin induced gene 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of INSIG1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:342,302...350,515
Ensembl chr 4:342,302...350,515
|
|
G |
Itgb4 |
integrin subunit beta 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ITGB4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:104,524,000...104,560,180
Ensembl chr10:104,523,996...104,561,078
|
|
G |
Itgb5 |
integrin subunit beta 5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ITGB5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:70,056,500...70,172,164
Ensembl chr11:70,056,500...70,172,372
|
|
G |
Jag2 |
jagged canonical Notch ligand 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of JAG2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:137,711,144...137,733,331
Ensembl chr 6:137,711,155...137,733,026
|
|
G |
Jmjd8 |
jumonji domain containing 8 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of JMJD8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:15,195,954...15,198,870
Ensembl chr10:15,195,969...15,198,868
|
|
G |
Jup |
junction plakoglobin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of JUP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:88,280,517...88,307,451
Ensembl chr10:88,279,632...88,307,412
|
|
G |
Kat8 |
lysine acetyltransferase 8 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of KAT8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:199,360,645...199,372,925
Ensembl chr 1:199,360,645...199,372,923
|
|
G |
Kb15 |
type II keratin Kb15 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of KRT6C mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:143,208,034...143,217,771
Ensembl chr 7:143,208,527...143,217,535
|
|
G |
Klf6 |
Kruppel-like factor 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of KLF6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:67,887,939...67,945,052
Ensembl chr17:67,887,939...67,945,037
|
|
G |
Kntc1 |
kinetochore associated 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of KNTC1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:38,200,463...38,274,162
Ensembl chr12:38,200,463...38,274,036
|
|
G |
Krba1 |
KRAB-A domain containing 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of KRBA1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:78,024,867...78,046,330
Ensembl chr 4:78,024,765...78,046,066
|
|
G |
Krt16 |
keratin 16 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of KRT16 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:88,149,210...88,152,167
Ensembl chr10:88,149,345...88,152,064
|
|
G |
Krt5 |
keratin 5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of KRT5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:143,320,142...143,324,536
Ensembl chr 7:143,316,920...143,453,546
|
|
G |
Krtcap2 |
keratinocyte associated protein 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of KRTCAP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:188,561,548...188,565,544
Ensembl chr 2:188,561,429...188,565,544
|
|
G |
Lamtor4 |
late endosomal/lysosomal adaptor, MAPK and MTOR activator 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LAMTOR4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:19,573,909...19,577,625
Ensembl chr12:19,573,909...19,577,624
|
|
G |
Lbh |
LBH regulator of WNT signaling pathway |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LBH mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:24,154,207...24,184,217
Ensembl chr 6:24,160,226...24,181,866
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LDLR mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:22,750,425...22,773,305
Ensembl chr 8:22,750,336...22,774,903
|
|
G |
Lgals1 |
galectin 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LGALS1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:120,153,184...120,156,290
Ensembl chr 7:120,153,184...120,156,289
|
|
G |
Lima1 |
LIM domain and actin binding 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of LIMA1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:141,428,113...141,528,447
Ensembl chr 7:141,428,063...141,528,397
|
|
G |
Litaf |
lipopolysaccharide-induced TNF factor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of LITAF mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:4,753,546...4,763,272
Ensembl chr10:4,719,713...4,763,510
|
|
G |
Lix1l |
limb and CNS expressed 1 like |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LIX1L mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:198,726,110...198,751,987
Ensembl chr 2:198,726,118...198,751,985
|
|
G |
Lmod3 |
leiomodin 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LMOD3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:129,604,378...129,619,136
Ensembl chr 4:129,604,267...129,619,142
|
|
G |
LOC100912373 |
uncharacterized LOC100912373 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of C8ORF88 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:28,480,029...28,505,430
Ensembl chr 5:28,480,023...28,505,432
|
|
G |
Lpin1 |
lipin 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LPIN1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:41,796,214...41,905,149
Ensembl chr 6:41,799,749...41,870,046
|
|
G |
Lrrc20 |
leucine rich repeat containing 20 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LRRC20 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:31,069,406...31,202,502
Ensembl chr20:31,096,214...31,202,514
|
|
G |
Luzp1 |
leucine zipper protein 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LUZP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:154,831,697...154,907,646
Ensembl chr 5:154,868,534...154,907,634
|
|
G |
Lyrm2 |
LYR motif containing 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LYRM2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:48,047,913...48,050,191
Ensembl chr 5:48,047,913...48,050,187
|
|
G |
Manf |
mesencephalic astrocyte-derived neurotrophic factor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MANF mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:115,623,175...115,626,408
Ensembl chr 8:115,623,178...115,626,380
|
|
G |
Map7d1 |
MAP7 domain containing 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MAP7D1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:144,250,416...144,274,981
Ensembl chr 5:144,250,419...144,274,981
|
|
G |
Mat2b |
methionine adenosyltransferase 2B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MAT2B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:25,832,096...25,848,045
Ensembl chr10:25,832,072...25,847,994
|
|
G |
Mbtps1 |
membrane-bound transcription factor peptidase, site 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MBTPS1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:52,146,507...52,206,310
Ensembl chr19:52,146,808...52,206,310
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MCM7 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:19,306,615...19,313,877
Ensembl chr12:19,306,607...19,314,016
|
|
G |
Med7 |
mediator complex subunit 7 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MED7 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:31,532,190...31,536,405
Ensembl chr10:31,532,250...31,536,405
|
|
G |
Mfsd3 |
major facilitator superfamily domain containing 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MFSD3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:117,763,395...117,765,904
Ensembl chr 7:117,763,783...117,766,464
|
|
G |
Mgarp |
mitochondria-localized glutamic acid-rich protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MGARP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:140,444,963...140,453,719
Ensembl chr 2:140,444,965...140,453,107
|
|
G |
Mgat2 |
alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MGAT2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:91,476,698...91,479,187
Ensembl chr 6:91,476,698...91,479,183
|
|
G |
Mlkl |
mixed lineage kinase domain like pseudokinase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MLKL mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:43,508,416...43,535,050
Ensembl chr19:43,506,976...43,528,851
|
|
G |
Mmachc |
metabolism of cobalamin associated C |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MMACHC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:135,555,587...135,561,723
Ensembl chr 5:135,555,565...135,561,914
|
|
G |
Mms19 |
MMS19 homolog, cytosolic iron-sulfur assembly component |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MMS19 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:261,191,646...261,229,070
Ensembl chr 1:261,191,646...261,229,046
|
|
G |
Mpdz |
multiple PDZ domain crumbs cell polarity complex component |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MPDZ mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:99,413,184...99,566,356
Ensembl chr 5:99,413,187...99,566,318
|
|
G |
Mpzl2 |
myelin protein zero-like 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MPZL2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:49,342,067...49,353,080
Ensembl chr 8:49,342,067...49,353,080
|
|
G |
Mrpl32 |
mitochondrial ribosomal protein L32 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MRPL32 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:53,102,534...53,105,400
Ensembl chr17:53,102,534...53,105,400
|
|
G |
Mrpl35 |
mitochondrial ribosomal protein L35 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MRPL35 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:99,738,792...99,749,665
Ensembl chr 4:99,738,792...99,746,560
|
|
G |
Mrps18c |
mitochondrial ribosomal protein S18C |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MRPS18C mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:10,440,691...10,446,909
Ensembl chr14:10,440,691...10,446,909
|
|
G |
Mrps21 |
mitochondrial ribosomal protein S21 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MRPS21 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:197,974,758...197,982,385
Ensembl chr 2:197,974,761...197,982,385
|
|
G |
Msh3 |
mutS homolog 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MSH3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:21,790,048...21,931,791
Ensembl chr 2:21,790,044...21,931,720
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MT2A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
|
|
G |
Mtfr2 |
mitochondrial fission regulator 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MTFR2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:15,834,779...15,850,424
Ensembl chr 1:15,782,477...15,860,624
|
|
G |
Mtif3 |
mitochondrial translational initiation factor 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MTIF3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:9,846,355...9,857,548
Ensembl chr12:9,846,398...9,857,548
|
|
G |
Mturn |
maturin, neural progenitor differentiation regulator homolog |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MTURN mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:84,854,341...84,875,300
Ensembl chr 4:84,854,386...84,871,757
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MVD mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:55,258,910...55,268,933
Ensembl chr19:55,258,905...55,268,951
|
|
G |
Myadm |
myeloid-associated differentiation marker |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MYADM mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:64,438,465...64,448,332
Ensembl chr 1:64,438,472...64,446,818
|
|
G |
Myh9 |
myosin, heavy chain 9 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MYH9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:118,740,005...118,792,507
Ensembl chr 7:118,741,110...118,792,625
|
|
G |
Myl6 |
myosin light chain 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MYL6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:2,906,137...2,909,193
Ensembl chr 7:2,906,137...2,909,179
|
|
G |
Myl6b |
myosin light chain 6B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MYL6B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:43,831,778...43,833,044
|
|
G |
Myl9 |
myosin light chain 9 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MYL9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:152,857,573...152,863,961
Ensembl chr 3:152,857,592...152,863,960
|
|
G |
Myo1b |
myosin Ib |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MYO1B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:54,706,005...54,766,054
Ensembl chr 9:54,558,202...54,766,054
|
|
G |
Mzf1 |
myeloid zinc finger 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MZF1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:65,520,827...65,533,233
Ensembl chr 1:65,522,118...65,533,212
|
|
G |
Mzt2b |
mitotic spindle organizing protein 2B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MZT2A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:89,276,869...89,283,939
Ensembl chr11:89,277,039...89,282,929
|
|
G |
Nasp |
nuclear autoantigenic sperm protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NASP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:135,446,485...135,472,113
Ensembl chr 5:135,446,962...135,472,116
|
|
G |
Nav2 |
neuron navigator 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NAV2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:104,575,765...104,941,554
Ensembl chr 1:104,576,589...104,941,552
|
|
G |
Ncapd2 |
non-SMC condensin I complex, subunit D2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NCAPD2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:157,682,855...157,705,903
Ensembl chr 4:157,683,077...157,704,596
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of NDRG1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:107,734,326...107,775,701
Ensembl chr 7:107,734,323...107,775,714
|
|
G |
Ndufa12 |
NADH:ubiquinone oxidoreductase subunit A12 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NDUFA12 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:35,125,516...35,163,182
Ensembl chr 7:35,125,424...35,167,406
|
|
G |
Ndufb3 |
NADH:ubiquinone oxidoreductase subunit B3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NDUFB3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:65,478,496...65,488,708
Ensembl chr 9:65,478,496...65,488,702
|
|
G |
Ndufb5 |
NADH:ubiquinone oxidoreductase subunit B5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NDUFB5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:119,139,717...119,153,753
Ensembl chr 2:119,139,717...119,153,753
|
|
G |
Ndufb6 |
NADH:ubiquinone oxidoreductase subunit B6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NDUFB6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:56,567,109...56,576,676
Ensembl chr 5:56,567,109...56,576,676
|
|
G |
Nelfe |
negative elongation factor complex member E |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NELFE mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:4,530,328...4,536,085
Ensembl chr20:4,530,342...4,536,209
|
|
G |
Neu1 |
neuraminidase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NEU1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:4,610,995...4,615,258
Ensembl chr20:4,610,995...4,615,247
|
|
G |
Nkiras2 |
NFKB inhibitor interacting Ras-like 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of NKIRAS2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:88,536,564...88,540,739
Ensembl chr10:88,536,626...88,540,733
|
|
G |
Nol6 |
nucleolar protein 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NOL6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:57,444,448...57,473,803
Ensembl chr 5:57,445,344...57,455,018
|
|
G |
Npm3 |
nucleophosmin/nucleoplasmin, 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NPM3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:265,504,105...265,506,080
Ensembl chr 1:265,504,575...265,506,046
|
|
G |
Nptx1 |
neuronal pentraxin 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of NPTX1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:108,682,637...108,691,592
Ensembl chr10:108,682,638...108,691,367
|
|
G |
Nsl1 |
NSL1 component of MIS12 kinetochore complex |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NSL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:109,669,646...109,697,849
Ensembl chr13:109,669,680...109,696,918
|
|
G |
Nudt2 |
nudix hydrolase 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NUDT2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:57,845,819...57,860,658
Ensembl chr 5:57,845,819...57,860,658
|
|
G |
Nufip2 |
nuclear FMR1 interacting protein 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NUFIP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:65,168,145...65,200,210
Ensembl chr10:65,176,648...65,200,109
|
|
G |
Osbp |
oxysterol binding protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of OSBP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:228,395,237...228,425,366
Ensembl chr 1:228,395,558...228,425,361
|
|
G |
Ost4 |
oligosaccharyltransferase complex subunit 4, non-catalytic |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of OST4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:26,836,216...26,837,440
Ensembl chr 6:26,836,216...26,837,440
|
|
G |
Pabpc1l |
poly(A) binding protein, cytoplasmic 1-like |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PABPC1L mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:160,410,733...160,447,073
Ensembl chr 3:160,410,757...160,444,940
|
|
G |
Pak1ip1 |
PAK1 interacting protein 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PAK1IP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:21,579,987...21,591,064
Ensembl chr17:21,580,087...21,591,203
|
|
G |
Pbdc1 |
polysaccharide biosynthesis domain containing 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PBDC1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:76,042,239...76,092,964
Ensembl chr X:76,042,239...76,046,938
|
|
G |
Pccb |
propionyl-CoA carboxylase subunit beta |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PCCB mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:109,368,887...109,418,871
Ensembl chr 8:109,368,624...109,418,872
|
|
G |
Pdia4 |
protein disulfide isomerase family A, member 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PDIA4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:77,470,636...77,489,535
Ensembl chr 4:77,470,636...77,489,535
|
|
G |
Pfkfb4 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PFKFB4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:117,733,347...117,776,525
Ensembl chr 8:117,737,117...117,775,386
|
|
G |
Phactr3 |
phosphatase and actin regulator 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PHACTR3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:173,798,542...173,871,386
Ensembl chr 3:173,798,545...173,871,904
|
|
G |
Phldb2 |
pleckstrin homology-like domain, family B, member 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PHLDB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:60,042,879...60,051,229
Ensembl chr11:57,265,732...57,481,589
|
|
G |
Plat |
plasminogen activator, tissue type |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PLAT mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:74,098,263...74,122,897
Ensembl chr16:74,098,260...74,122,889
|
|
G |
Plec |
plectin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PLEC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:117,230,319...117,291,859
Ensembl chr 7:117,230,319...117,289,961
|
|
G |
Plk2 |
polo-like kinase 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PLK2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:41,911,143...41,916,901
Ensembl chr 2:41,911,131...41,916,901
|
|
G |
Plxnb2 |
plexin B2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PLXNB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:130,135,484...130,161,568
Ensembl chr 7:130,135,464...130,151,880
|
|
G |
Poc1a |
POC1 centriolar protein A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of POC1A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:114,982,764...115,050,844
Ensembl chr 8:114,986,326...115,050,728
|
|
G |
Poglut3 |
protein O-glucosyltransferase 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of POGLUT3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:57,964,988...57,982,605
Ensembl chr 8:57,964,988...57,982,600
|
|
G |
Pole2 |
DNA polymerase epsilon 2, accessory subunit |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of POLE2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:91,494,348...91,532,355
Ensembl chr 6:91,494,393...91,518,996
|
|
G |
Polr3k |
RNA polymerase III subunit K |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of POLR3K mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:177,374,812...177,379,009
Ensembl chr 3:177,374,812...177,379,008
|
|
G |
Pop5 |
POP5 homolog, ribonuclease P/MRP subunit |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of POP5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:47,138,346...47,143,152
Ensembl chr12:47,138,346...47,142,852
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PPARGC1A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Ppic |
peptidylprolyl isomerase C |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PPIC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:48,372,039...48,384,645
Ensembl chr18:48,372,041...48,384,645
|
|
G |
Ppil3 |
peptidylprolyl isomerase like 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PPIL3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:65,315,407...65,329,145
Ensembl chr 9:65,315,410...65,329,066
|
|
G |
Ppp1r14c |
protein phosphatase 1, regulatory (inhibitor) subunit 14c |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PPP1R14C mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:39,811,314...39,923,071
Ensembl chr 1:39,811,314...39,923,057
|
|
G |
Ppp6r2 |
protein phosphatase 6, regulatory subunit 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PPP6R2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:130,188,609...130,260,209
Ensembl chr 7:130,227,456...130,259,609
|
|
G |
Ppwd1 |
peptidylprolyl isomerase domain and WD repeat containing 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PPWD1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:34,288,853...34,313,094
Ensembl chr 2:34,290,199...34,313,094
|
|
G |
Prickle1 |
prickle planar cell polarity protein 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PRICKLE1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:134,702,964...134,799,437
Ensembl chr 7:134,702,964...134,722,215
|
|
G |
Psmb10 |
proteasome 20S subunit beta 10 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PSMB10 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:37,909,543...37,912,027
Ensembl chr19:37,909,546...37,912,027
|
|
G |
Psmb6 |
proteasome 20S subunit beta 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PSMB6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:57,131,339...57,133,685
Ensembl chr10:57,131,386...57,133,637
|
|
G |
Psmg4 |
proteasome assembly chaperone 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PSMG4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:31,402,581...31,411,924
Ensembl chr17:31,404,578...31,411,957
|
|
G |
Pstpip2 |
proline-serine-threonine phosphatase-interacting protein 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PSTPIP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:74,173,809...74,291,188
Ensembl chr18:74,174,936...74,292,921
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PTGES mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:9,727,408...9,738,752
Ensembl chr 3:9,727,408...9,738,752
|
|
G |
Ptpre |
protein tyrosine phosphatase, receptor type, E |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PTPRE mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:207,820,719...207,987,123
Ensembl chr 1:207,887,209...207,987,136
|
|
G |
Pttg1 |
PTTG1 regulator of sister chromatid separation, securin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PTTG1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:29,014,332...29,026,088
Ensembl chr10:29,020,049...29,026,002
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PYCARD mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:199,438,029...199,439,062
Ensembl chr 1:199,437,832...199,439,210
|
|
G |
Qrich1 |
glutamine-rich 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of QRICH1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:117,305,803...117,346,738
Ensembl chr 8:117,307,339...117,346,736
|
|
G |
Rab25 |
RAB25, member RAS oncogene family |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RAB25 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:187,903,301...187,909,398
Ensembl chr 2:187,903,307...187,909,394
|
|
G |
Rab38 |
RAB38, member RAS oncogene family |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RAB38 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:152,072,716...152,153,449
Ensembl chr 1:152,072,665...152,153,449
|
|
G |
Rab8a |
RAB8A, member RAS oncogene family |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RAB8A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:19,355,047...19,376,776
Ensembl chr16:19,355,048...19,376,776
|
|
G |
Rad23b |
RAD23 homolog B, nucleotide excision repair protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RAD23B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:72,103,704...72,141,701
Ensembl chr 5:72,103,704...72,141,700
|
|
G |
Rasip1 |
Ras interacting protein 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RASIP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:101,609,209...101,621,648
Ensembl chr 1:101,610,773...101,621,646
|
|
G |
Rbck1 |
RANBP2-type and C3HC4-type zinc finger containing 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RBCK1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:147,793,014...147,809,941
Ensembl chr 3:147,793,017...147,809,919
|
|
G |
Rbm33 |
RNA binding motif protein 33 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RBM33 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:592,616...700,903
Ensembl chr 4:594,882...695,383
|
|
G |
Rbm5 |
RNA binding motif protein 5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RBM5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:116,502,941...116,532,178
Ensembl chr 8:116,502,937...116,532,169
|
|
G |
Rbms1 |
RNA binding motif, single stranded interacting protein 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RBMS1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:46,802,870...47,025,178
Ensembl chr 3:46,803,355...47,025,128
|
|
G |
Rer1 |
retention in endoplasmic reticulum sorting receptor 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RER1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:172,476,746...172,488,822
Ensembl chr 5:172,476,747...172,488,822
|
|
G |
Rfxank |
regulatory factor X-associated ankyrin-containing protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RFXANK mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:21,029,449...21,037,080
Ensembl chr16:21,029,596...21,037,078
|
|
G |
Rgl1 |
ral guanine nucleotide dissociation stimulator,-like 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RGL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:69,909,122...70,174,590
Ensembl chr13:69,909,096...70,174,565
|
|
G |
Rgs17 |
regulator of G-protein signaling 17 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RGS17 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:42,491,566...42,587,735
Ensembl chr 1:42,492,761...42,587,721
|
|
G |
Rgs20 |
regulator of G-protein signaling 20 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RGS20 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:14,367,498...14,494,048
Ensembl chr 5:14,415,606...14,494,756
|
|
G |
Rheb |
Ras homolog, mTORC1 binding |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RHEB mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:6,827,429...6,873,384
Ensembl chr 4:6,827,429...6,873,383
|
|
G |
Rhob |
ras homolog family member B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RHOB mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:33,689,127...33,691,301
Ensembl chr 6:33,689,127...33,691,301
|
|
G |
Rhoq |
ras homolog family member Q |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RHOQ mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:10,533,151...10,568,582
Ensembl chr 6:10,533,151...10,568,581
|
|
G |
Ripor2 |
RHO family interacting cell polarization regulator 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FAM65B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:42,324,594...42,549,907
Ensembl chr17:42,324,594...42,422,053
|
|
G |
Rnaset2 |
ribonuclease T2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RNASET2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:53,174,879...53,192,048
Ensembl chr 1:53,174,879...53,192,048
|
|
G |
Rnf126 |
ring finger protein 126 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RNF126 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:12,820,796...12,828,325
Ensembl chr 7:12,820,840...12,828,334
|
|
G |
Rnf20 |
ring finger protein 20 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RNF20 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:64,892,996...64,920,397
Ensembl chr 5:64,892,802...64,920,390
|
|
G |
Rnh1 |
ribonuclease/angiogenin inhibitor 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RNH1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:214,151,341...214,163,807
Ensembl chr 1:214,151,338...214,163,808
|
|
G |
Rpl10a |
ribosomal protein L10A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RPL10A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:7,908,309...7,910,867
Ensembl chr20:7,908,304...7,910,867
|
|
G |
Rpl27 |
ribosomal protein L27 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RPL27 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:89,352,864...89,356,563
Ensembl chr10:89,352,835...89,356,547
|
|
G |
Rpl34 |
ribosomal protein L34 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RPL34 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:235,850,281...235,854,021
Ensembl chr 2:235,850,334...235,852,708
|
|
G |
Rpp25l |
ribonuclease P/MRP subunit p25 like |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RPP25L mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:58,096,037...58,097,577
Ensembl chr 5:58,096,213...58,097,577
|
|
G |
Rpusd2 |
RNA pseudouridine synthase domain containing 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RPUSD2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:110,835,654...110,840,903
Ensembl chr 3:110,835,683...110,840,068
|
|
G |
Rragd |
Ras-related GTP binding D |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RRAGD mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:48,224,994...48,260,691
Ensembl chr 5:48,224,994...48,260,685
|
|
G |
S100a10 |
S100 calcium binding protein A10 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of S100A10 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:193,892,589...193,901,236
Ensembl chr 2:193,892,589...193,901,236
|
|
G |
S100a14 |
S100 calcium binding protein A14 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of S100A14 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:189,913,433...189,919,947
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of S100A8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:190,073,239...190,074,333
Ensembl chr 2:190,073,815...190,074,354
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of S100A9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:190,097,436...190,100,209
Ensembl chr 2:190,097,554...190,100,276
|
|
G |
Sc5d |
sterol-C5-desaturase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SC5D mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:46,525,406...46,537,014
Ensembl chr 8:46,525,400...46,537,050
|
|
G |
Scara3 |
scavenger receptor class A, member 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SCARA3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr15:42,605,505...42,638,409
Ensembl chr15:42,605,473...42,638,392
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SCD mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
|
|
G |
Sdhaf2 |
succinate dehydrogenase complex assembly factor 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SDHAF2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:226,543,671...226,572,414
Ensembl chr 1:226,547,531...226,572,349
|
|
G |
Sdhb |
succinate dehydrogenase complex iron sulfur subunit B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SDHB mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:159,484,378...159,505,063
Ensembl chr 5:159,484,370...159,505,064
|
|
G |
Sec13 |
SEC13 homolog, nuclear pore and COPII coat complex component |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SEC13 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:145,686,186...145,699,577
Ensembl chr 4:145,686,193...145,699,577
|
|
G |
Sec61g |
SEC61 translocon subunit gamma |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SEC61G mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:99,774,589...99,780,964
Ensembl chr14:99,774,589...99,780,964
|
|
G |
Selenon |
selenoprotein N |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SEPN1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:152,748,497...152,765,489
Ensembl chr 5:152,750,284...152,762,165
|
|
G |
Selenos |
selenoprotein S |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SELS mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:126,979,579...126,989,344
Ensembl chr 1:126,979,575...126,989,344
|
|
G |
Sem1 |
SEM1, 26S proteasome complex subunit |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SEM1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:32,067,444...32,087,600
Ensembl chr 4:32,067,444...32,087,600
|
|
G |
Serpinb1a |
serpin family B member 1A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SERPINB1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:32,903,089...32,911,498
Ensembl chr17:32,904,119...32,911,495
|
|
G |
Serpinb2 |
serpin family B member 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SERPINB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:27,449,907...27,463,015
Ensembl chr13:27,449,934...27,463,010
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SERPINE1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Sfn |
stratifin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SFN mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:151,823,422...151,824,937
Ensembl chr 5:151,823,887...151,824,633
|
|
G |
Sfxn4 |
sideroflexin 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SFXN4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:282,213,610...282,236,851
Ensembl chr 1:282,213,675...282,235,974
|
|
G |
Sgpp2 |
sphingosine-1-phosphate phosphatase 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SGPP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:84,203,094...84,321,269
Ensembl chr 9:84,203,072...84,319,874
|
|
G |
Sh2b3 |
SH2B adaptor protein 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SH2B3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:40,261,990...40,265,757
Ensembl chr12:40,244,081...40,265,757
|
|
G |
Slc11a2 |
solute carrier family 11 member 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SLC11A2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:142,025,812...142,062,892
Ensembl chr 7:142,025,815...142,063,212
|
|
G |
Slc26a6 |
solute carrier family 26 member 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SLC26A6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:117,648,792...117,659,376
Ensembl chr 8:117,648,745...117,659,804
|
|
G |
Slc43a3 |
solute carrier family 43, member 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SLC43A3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:72,328,912...72,351,039
Ensembl chr 3:72,329,967...72,351,111
|
|
G |
Slc44a1 |
solute carrier family 44 member 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SLC44A1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:70,243,643...70,424,115
Ensembl chr 5:70,245,843...70,424,112
|
|
G |
Slf2 |
SMC5-SMC6 complex localization factor 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SLF2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:264,670,836...264,733,465
Ensembl chr 1:264,670,841...264,733,306
|
|
G |
Snip1 |
Smad nuclear interacting protein 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SNIP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr15:19,275,273...19,282,753
Ensembl chr 5:143,063,099...143,070,884
|
|
G |
Snrnp25 |
small nuclear ribonucleoprotein U11/U12 subunit 25 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SNRNP25 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:15,685,999...15,689,338
Ensembl chr10:15,686,008...15,689,325
|
|
G |
Snx8 |
sorting nexin 8 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SNX8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:16,340,917...16,389,500
Ensembl chr12:16,340,922...16,389,497
|
|
G |
Sox15 |
SRY-box transcription factor 15 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SOX15 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:56,260,514...56,263,503
Ensembl chr10:56,260,514...56,263,503
|
|
G |
Spa17 |
sperm autoantigenic protein 17 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SPA17 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:40,066,954...40,078,131
Ensembl chr 8:40,067,076...40,078,165
|
|
G |
Spats2l |
spermatogenesis associated, serine-rich 2-like |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SPATS2L mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:64,643,223...64,843,963
Ensembl chr 9:64,643,281...64,843,960
|
|
G |
Sphk1 |
sphingosine kinase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SPHK1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:105,498,728...105,504,401
Ensembl chr10:105,498,728...105,504,393
|
|
G |
Sphk2 |
sphingosine kinase 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SPHK2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:101,692,972...101,700,604
Ensembl chr 1:101,692,973...101,697,277
|
|
G |
Spry2 |
sprouty RTK signaling antagonist 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SPRY2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr15:90,172,769...90,177,823
Ensembl chr15:90,172,975...90,175,802
|
|
G |
Srp54a |
signal recognition particle 54A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SRP54 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:75,996,629...76,035,768
Ensembl chr 6:75,996,643...76,034,083
|
|
G |
St14 |
ST14 transmembrane serine protease matriptase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ST14 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:32,240,113...32,280,813
Ensembl chr 8:32,240,133...32,280,869
|
|
G |
Stk26 |
serine/threonine kinase 26 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of STK26 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:138,032,356...138,096,632
Ensembl chr X:138,046,494...138,096,669
|
|
G |
Stmn1 |
stathmin 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of STMN1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:152,680,412...152,686,807
Ensembl chr 5:152,680,407...152,686,806
|
|
G |
Stx8 |
syntaxin 8 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of STX8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:54,512,922...54,753,302
Ensembl chr10:54,512,983...54,753,302
|
|
G |
Tacstd2 |
tumor-associated calcium signal transducer 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TACSTD2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:98,341,187...98,342,887
Ensembl chr 4:98,341,188...98,342,887
|
|
G |
Tagln |
transgelin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TAGLN mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:50,222,895...50,228,369
Ensembl chr 8:50,222,896...50,231,357
|
|
G |
Tamm41 |
TAM41 mitochondrial translocator assembly and maintenance homolog |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TAMM41 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:146,922,085...146,954,159
Ensembl chr 4:146,922,085...146,954,159
|
|
G |
Tbc1d31 |
TBC1 domain family, member 31 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of WDR67 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:97,778,260...97,839,668
Ensembl chr 7:97,760,134...97,839,668
|
|
G |
Tbc1d32 |
TBC1 domain family, member 32 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TBC1D32 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:37,463,879...37,701,268
Ensembl chr20:37,465,278...37,700,937
|
|
G |
Tcea2 |
transcription elongation factor A2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TCEA2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:177,187,686...177,195,898
Ensembl chr 3:177,188,044...177,195,894
|
|
G |
Tceal3 |
transcription elongation factor A like 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TCEAL3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:107,322,077...107,324,054
Ensembl chr 2:102,370,158...102,370,757 Ensembl chr X:102,370,158...102,370,757
|
|
G |
Tceal9 |
transcription elongation factor A like 9 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TCEAL9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:106,791,333...106,794,667
Ensembl chr X:106,791,333...106,794,657
|
|
G |
Tcerg1 |
transcription elongation regulator 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TCERG1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:36,796,290...36,889,966
Ensembl chr18:36,829,062...36,889,966
|
|
G |
Tent5b |
terminal nucleotidyltransferase 5B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FAM46B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:151,692,068...151,699,381
Ensembl chr 5:151,692,108...151,700,246
|
|
G |
Tfb1m |
transcription factor B1, mitochondrial |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TFB1M mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:44,433,116...44,474,674
Ensembl chr 1:44,433,116...44,474,674
|
|
G |
Tfpi |
tissue factor pathway inhibitor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TFPI mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:71,852,738...71,902,127
Ensembl chr 3:71,852,744...71,893,618
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TGFA mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:117,961,877...118,045,923
Ensembl chr 4:117,962,319...118,046,344
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TGFBR2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:124,310,288...124,399,345
Ensembl chr 8:124,312,754...124,399,494
|
|
G |
Tgm2 |
transglutaminase 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TGM2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:154,597,165...154,627,257
Ensembl chr 3:154,597,168...154,627,257
|
|
G |
Thbd |
thrombomodulin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of THBD mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:142,748,673...142,752,325
Ensembl chr 3:142,748,674...142,752,325
|
|
G |
Timm22 |
translocase of inner mitochondrial membrane 22 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TIMM22 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:64,556,064...64,563,822
Ensembl chr10:64,556,064...64,563,822
|
|
G |
Timm23 |
translocase of inner mitochondrial membrane 23 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TIMM23 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:8,324,038...8,350,067
Ensembl chr16:8,324,036...8,350,067
|
|
G |
Tinf2 |
TERF1 interacting nuclear factor 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TINF2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr15:34,358,697...34,365,085
Ensembl chr15:34,360,974...34,364,081
|
|
G |
Tiparp |
TCDD-inducible poly(ADP-ribose) polymerase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TIPARP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:157,316,293...157,342,979
Ensembl chr 2:157,316,266...157,341,469
|
|
G |
Tmem44 |
transmembrane protein 44 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TMEM44 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:73,737,323...73,774,149
Ensembl chr11:73,738,433...73,774,190
|
|
G |
Tmem50b |
transmembrane protein 50B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TMEM50B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:31,719,441...31,752,276
Ensembl chr11:31,719,443...31,752,243
|
|
G |
Tmem54 |
transmembrane protein 54 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TMEM54 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:147,288,700...147,295,191
Ensembl chr 5:147,288,723...147,296,702
|
|
G |
Tmub2 |
transmembrane and ubiquitin-like domain containing 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TMUB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:90,230,428...90,234,874
Ensembl chr10:90,230,441...90,234,873
|
|
G |
Tnc |
tenascin C |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TNC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:79,789,686...79,874,555
Ensembl chr 5:79,789,671...79,874,671
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TNFAIP3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:14,401,103...14,416,369
Ensembl chr 1:14,402,913...14,412,807
|
|
G |
Tnfaip8l3 |
TNF alpha induced protein 8 like 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TNFAIP8L3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:58,599,382...58,648,045
Ensembl chr 8:58,602,127...58,647,933
|
|
G |
Tomm6 |
translocase of outer mitochondrial membrane 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TOMM6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:15,313,346...15,314,872
Ensembl chr 9:15,313,523...15,314,435
|
|
G |
Tomm7 |
translocase of outer mitochondrial membrane 7 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TOMM7 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:7,835,949...7,842,790
Ensembl chr 4:7,835,949...7,842,789
|
|
G |
Tp63 |
tumor protein p63 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TP63 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:78,234,853...78,456,559
Ensembl chr11:78,234,800...78,456,501
|
|
G |
Tpd52l1 |
TPD52 like 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TPD52L1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:28,454,949...28,578,736
Ensembl chr 1:28,454,966...28,576,553
|
|
G |
Tpd52l2 |
TPD52 like 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which affects the expression of TPD52L2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:176,989,333...177,009,425
Ensembl chr 3:176,989,672...177,008,419
|
|
G |
Trim33 |
tripartite motif-containing 33 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TRIM33 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:205,783,252...205,863,426
Ensembl chr 2:205,783,252...205,858,433
|
|
G |
Trim47 |
tripartite motif-containing 47 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TRIM47 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:104,654,717...104,659,188
Ensembl chr10:104,654,717...104,659,188
|
|
G |
Tsen15 |
tRNA splicing endonuclease subunit 15 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TSEN15 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:69,765,093...69,781,019
Ensembl chr13:69,765,091...69,781,019
|
|
G |
Tspan9 |
tetraspanin 9 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TSPAN9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:160,530,726...160,725,056
Ensembl chr 4:160,530,720...160,662,974
|
|
G |
Tspo |
translocator protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TSPO mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:124,460,358...124,470,610
Ensembl chr 7:124,460,358...124,470,609
|
|
G |
Tubb2a |
tubulin, beta 2A class IIa |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TUBB2A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:31,493,145...31,496,827
Ensembl chr17:31,493,107...31,498,651
|
|
G |
Twist1 |
twist family bHLH transcription factor 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TWIST1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:53,401,241...53,403,235
Ensembl chr 6:53,401,109...53,403,214
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TXN mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:75,049,735...75,057,731
Ensembl chr 5:75,049,747...75,057,752
|
|
G |
Txnip |
thioredoxin interacting protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TXNIP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:198,683,168...198,686,971
Ensembl chr 2:198,683,159...198,686,974
|
|
G |
Ube2j1 |
ubiquitin-conjugating enzyme E2, J1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of UBE2J1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:48,274,387...48,292,699
Ensembl chr 5:48,274,477...48,290,658
|
|
G |
Ube2n |
ubiquitin-conjugating enzyme E2N |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of UBE2N mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:36,610,147...36,640,190
Ensembl chr 7:36,610,147...36,640,189
|
|
G |
Uimc1 |
ubiquitin interaction motif containing 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of UIMC1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:10,061,915...10,130,921
Ensembl chr17:10,065,947...10,130,907
|
|
G |
Uros |
uroporphyrinogen III synthase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of UROS mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:205,755,766...205,778,170
Ensembl chr 1:205,756,640...205,777,167
|
|
G |
Usp13 |
ubiquitin specific peptidase 13 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of USP13 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:119,197,153...119,317,507
Ensembl chr 2:119,197,239...119,317,500
|
|
G |
Vasn |
vasorin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of VASN mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:11,121,041...11,131,548
Ensembl chr10:11,121,041...11,131,548
|
|
G |
Vps37b |
VPS37B subunit of ESCRT-I |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of VPS37B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:37,984,790...38,023,369
Ensembl chr12:37,984,790...38,023,368
|
|
G |
Vps72 |
vacuolar protein sorting 72 homolog |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of VPS72 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:196,277,961...196,289,549
Ensembl chr 2:196,277,978...196,289,561
|
|
G |
Wasf2 |
WASP family member 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of WASF2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:151,319,382...151,385,051
Ensembl chr 5:151,343,493...151,381,238
|
|
G |
Xpnpep1 |
X-prolyl aminopeptidase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of XPNPEP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:273,708,217...273,758,247
Ensembl chr 1:273,708,212...273,758,442
|
|
G |
Zc3h4 |
zinc finger CCCH-type containing 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ZC3H4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:78,352,833...78,390,906
Ensembl chr 1:78,354,934...78,390,907
|
|
G |
Zfp185 |
zinc finger protein 185 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ZNF185 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:152,989,099...153,034,289
Ensembl chr X:152,999,016...153,031,444
|
|
G |
Zswim1 |
zinc finger, SWIM-type containing 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ZSWIM1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:161,287,884...161,292,466
Ensembl chr 3:161,290,391...161,291,758
|
|
G |
Zyx |
zyxin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ZYX mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:71,740,188...71,749,386
Ensembl chr 4:71,740,532...71,749,386
|
|
|
G |
A4galt |
alpha 1,4-galactosyltransferase (P blood group) |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of A4GALT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:124,085,832...124,110,440
Ensembl chr 7:124,085,834...124,089,385
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ABCG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Ak5 |
adenylate kinase 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of AK5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:257,671,772...257,864,385
Ensembl chr 2:257,671,772...257,864,385
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:30768133 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ALDOC mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:65,586,504...65,590,093
Ensembl chr10:65,586,504...65,590,126
|
|
G |
Amhr2 |
anti-Mullerian hormone receptor type 2 |
increases expression |
EXP |
diisobutyl phthalate results in increased expression of AMHR2 mRNA |
CTD |
PMID:22112501 |
|
NCBI chr 7:144,052,202...144,060,678
Ensembl chr 7:144,052,061...144,060,685
|
|
G |
Ar |
androgen receptor |
affects binding multiple interactions |
EXP ISO |
diisobutyl phthalate binds to AR protein diisobutyl phthalate inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; diisobutyl phthalate inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein] |
CTD |
PMID:14565775 PMID:15840436 PMID:28571686 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Arnt2 |
aryl hydrocarbon receptor nuclear translocator 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ARNT2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:146,399,217...146,556,437
Ensembl chr 1:146,399,217...146,556,171
|
|
G |
Astn1 |
astrotactin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ASTN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:76,054,965...76,370,674
Ensembl chr13:76,055,410...76,370,674
|
|
G |
Astn2 |
astrotactin 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ASTN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:81,179,614...82,168,528
Ensembl chr 5:81,179,605...82,168,427
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ATP1A3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:81,852,423...81,881,565
Ensembl chr 1:81,852,429...81,881,549
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BAX mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcat1 |
branched chain amino acid transaminase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BCAT1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:179,259,305...179,340,021
Ensembl chr 4:179,259,308...179,339,795
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of BCL2 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bend6 |
BEN domain containing 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BEND6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:38,297,253...38,351,312
Ensembl chr 9:38,297,322...38,351,024
|
|
G |
Bpgm |
bisphosphoglycerate mutase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BPGM mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:61,912,210...61,940,697
Ensembl chr 4:61,912,210...61,940,696
|
|
G |
Cacng7 |
calcium voltage-gated channel auxiliary subunit gamma 7 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CACNG7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:64,374,547...64,405,380
Ensembl chr 1:64,374,603...64,405,149
|
|
G |
Cadm3 |
cell adhesion molecule 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CADM3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:91,842,311...91,873,126
Ensembl chr13:91,842,333...91,873,096
|
|
G |
Cadps |
calcium dependent secretion activator |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CADPS mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:15,275,489...15,690,575
Ensembl chr15:15,275,541...15,667,778
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CAMK4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:25,746,878...25,975,962
Ensembl chr18:25,749,098...25,965,957
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CASP8 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CAT mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CCND2 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of CDKN2A mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
|
|
G |
Celsr3 |
cadherin, EGF LAG seven-pass G-type receptor 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CELSR3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:117,620,293...117,648,034
Ensembl chr 8:117,620,317...117,648,028
|
|
G |
Chga |
chromogranin A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CHGA mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:126,434,226...126,445,569
Ensembl chr 6:126,434,226...126,445,568
|
|
G |
Chgb |
chromogranin B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CHGB mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:125,428,050...125,441,601
Ensembl chr 3:125,428,260...125,441,594
|
|
G |
Cited1 |
Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CITED1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:72,128,996...72,133,692
Ensembl chr X:72,128,994...72,133,692
|
|
G |
Clstn3 |
calsyntenin 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CLSTN3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:157,044,736...157,078,013
Ensembl chr 4:157,043,925...157,078,130
|
|
G |
Cntnap1 |
contactin associated protein 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CNTNAP1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:89,087,904...89,103,615
Ensembl chr10:89,089,646...89,103,614
|
|
G |
Crmp1 |
collapsin response mediator protein 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CRMP1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:78,266,931...78,312,777
Ensembl chr14:78,266,931...78,308,933
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
EXP ISO |
diisobutyl phthalate results in decreased expression of CYP11A1 mRNA; diisobutyl phthalate results in decreased expression of CYP11A1 protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CYP11A1 mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:16458459 PMID:21633115 PMID:22112501 PMID:28013214 PMID:30802670 |
|
NCBI chr 8:62,798,317...62,809,848
Ensembl chr 8:62,779,875...62,809,893
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of CYP11B1 mRNA |
CTD |
PMID:22112501 |
|
NCBI chr 7:116,248,759...116,255,205
Ensembl chr 7:116,156,219...116,255,167
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
EXP ISO |
diisobutyl phthalate results in decreased expression of CYP17A1 mRNA [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:22112501 PMID:28655647 PMID:30802670 |
|
NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CYP19A1 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
|
|
G |
Dclk3 |
doublecortin-like kinase 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DCLK3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:119,691,567...119,744,484
Ensembl chr 8:119,691,388...119,744,506
|
|
G |
Ddc |
dopa decarboxylase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DDC mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:91,905,919...91,996,816
Ensembl chr14:91,905,919...91,996,774
|
|
G |
Dock3 |
dedicator of cyto-kinesis 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DOCK3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:115,627,282...115,982,260
Ensembl chr 8:115,629,583...115,981,910
|
|
G |
Dpf1 |
double PHD fingers 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DPF1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:87,248,448...87,258,070
Ensembl chr 1:87,248,489...87,258,070
|
|
G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DYNC1I1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:30,807,755...31,121,097
Ensembl chr 4:30,807,879...31,121,090
|
|
G |
Ece2 |
endothelin-converting enzyme 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ECE2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:83,948,896...83,985,429
Ensembl chr11:83,948,230...83,964,055
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EDN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Elmod1 |
ELMO domain containing 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ELMOD1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:58,486,078...58,542,884
Ensembl chr 8:58,486,078...58,542,844
|
|
G |
Emx2 |
empty spiracles homeobox 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EMX2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:280,633,938...280,640,946
Ensembl chr 1:280,633,938...280,640,946
|
|
G |
Epdr1 |
ependymin related 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EPDR1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:47,397,558...47,422,183
Ensembl chr17:47,397,558...47,422,182
|
|
G |
Espn |
espin |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ESPN mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:169,293,356...169,331,338
Ensembl chr 5:169,293,904...169,331,163
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases activity |
ISO |
diisobutyl phthalate binds to and results in increased activity of ESR1 protein; diisobutyl phthalate inhibits the reaction [Estradiol results in increased activity of ESR1 protein]; Tamoxifen inhibits the reaction [diisobutyl phthalate binds to and results in increased activity of ESR1 protein] diisobutyl phthalate results in increased activity of ESR1 protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ESR1 mRNA |
CTD |
PMID:15840436 PMID:27633901 PMID:28013214 PMID:28571686 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions increases activity |
ISO |
diisobutyl phthalate binds to and results in increased activity of ESR2 protein; diisobutyl phthalate inhibits the reaction [Estradiol results in increased activity of ESR2 protein] diisobutyl phthalate results in increased activity of ESR2 protein |
CTD |
PMID:27633901 PMID:28571686 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FABP5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:93,981,662...93,985,322
Ensembl chr 2:93,981,656...93,985,378
|
|
G |
Fam163a |
family with sequence similarity 163, member A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FAM163A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:73,741,674...73,820,114
Ensembl chr13:73,741,679...73,819,896
|
|
G |
Fez1 |
fasciculation and elongation protein zeta 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FEZ1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:39,305,128...39,350,270
Ensembl chr 8:39,305,128...39,350,270
|
|
G |
Fkbp1b |
FKBP prolyl isomerase 1B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FKBP1B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:29,975,863...29,987,252
Ensembl chr 6:29,977,797...29,987,451
|
|
G |
Flg |
filaggrin |
multiple interactions |
ISO |
[FLG gene polymorphism affects the susceptibility to diisobutyl phthalate] which affects the abundance of mono-isobutyl phthalate |
CTD |
PMID:24380925 |
|
NCBI chr 2:193,565,401...193,574,297
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FSHR mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 6:12,796,383...12,997,817
Ensembl chr 6:12,796,383...12,997,817
|
|
G |
Fxyd7 |
FXYD domain-containing ion transport regulator 7 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FXYD7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:89,474,601...89,484,069
Ensembl chr 1:89,474,601...89,483,988
|
|
G |
Gfra3 |
GDNF family receptor alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GFRA3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:27,491,860...27,520,133
Ensembl chr18:27,491,845...27,520,295
|
|
G |
Gfra4 |
GDNF family receptor alpha 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GFRA4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:123,573,394...123,582,431
Ensembl chr 3:123,578,997...123,581,518
|
|
G |
Ggta1 |
glycoprotein alpha-galactosyltransferase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GGTA1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:14,614,099...14,701,185
Ensembl chr 3:14,614,122...14,644,951
|
|
G |
Gng2 |
G protein subunit gamma 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GNG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:4,748,242...4,853,555
Ensembl chr15:4,850,122...4,853,555
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GPX1 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GSR mRNA |
CTD |
PMID:28013214 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GSTA3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:27,357,490...27,417,023
Ensembl chr 9:27,402,381...27,417,023
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of HMGCR mRNA |
CTD |
PMID:28655647 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of HMGCS1 mRNA |
CTD |
PMID:28655647 |
|
NCBI chr 2:52,427,351...52,445,082
Ensembl chr 2:52,431,601...52,445,055
|
|
G |
Hoxb8 |
homeo box B8 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HOXB8 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:84,131,484...84,133,874
Ensembl chr10:84,131,495...84,133,246
|
|
G |
Hoxd3 |
homeo box D3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HOXD3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:61,650,569...61,670,285
Ensembl chr 3:61,658,245...61,670,282
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
increases expression |
EXP |
diisobutyl phthalate results in increased expression of HSD17B3 mRNA |
CTD |
PMID:28655647 |
|
NCBI chr17:1,579,319...1,610,745
Ensembl chr17:1,579,319...1,610,745
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HSD3B1 mRNA |
CTD |
PMID:28013214 |
|
|
|
G |
Hspa12a |
heat shock protein family A (Hsp70) member 12A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HSPA12A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:279,946,809...280,104,366
Ensembl chr 1:279,946,811...280,015,358
|
|
G |
Ido2 |
indoleamine 2,3-dioxygenase 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of IDO2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr16:72,232,852...72,291,227
Ensembl chr16:72,268,943...72,289,156
|
|
G |
Insl3 |
insulin-like 3 |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of INSL3 mRNA |
CTD |
PMID:22112501 |
|
NCBI chr16:20,120,753...20,122,702
Ensembl chr16:20,121,352...20,122,696
|
|
G |
Kif5c |
kinesin family member 5C |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of KIF5C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:35,014,157...35,257,417
Ensembl chr 3:35,014,538...35,257,407
|
|
G |
L1cam |
L1 cell adhesion molecule |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of L1CAM mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:156,901,244...156,928,064
Ensembl chr X:156,909,913...156,928,057
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LCN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
|
|
G |
Lonrf2 |
LON peptidase N-terminal domain and ring finger 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LONRF2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:45,468,001...45,506,448
Ensembl chr 9:45,466,688...45,505,767
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of LPL mRNA |
CTD |
PMID:30768133 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Lrrc4b |
leucine rich repeat containing 4B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LRRC4B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:100,434,418...100,468,914
Ensembl chr 1:100,447,998...100,468,868
|
|
G |
Lynx1 |
Ly6/neurotoxin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LYNX1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:115,982,877...115,988,121
Ensembl chr 7:115,982,876...115,988,090
|
|
G |
Map6 |
microtubule-associated protein 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MAP6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:164,225,776...164,292,094
Ensembl chr 1:164,225,934...164,292,093
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MAPT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Mir141 |
microRNA 141 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR141 |
CTD |
PMID:31199487 |
|
NCBI chr 4:157,236,346...157,236,439
Ensembl chr 4:157,236,346...157,236,439
|
|
G |
Mir184 |
microRNA 184 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR184 |
CTD |
PMID:31199487 |
|
NCBI chr 8:97,175,657...97,175,733
Ensembl chr 8:97,175,657...97,175,733
|
|
G |
Mllt11 |
MLLT11, transcription factor 7 cofactor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MLLT11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:196,392,936...196,402,106
Ensembl chr 2:196,392,938...196,402,106
|
|
G |
Ncs1 |
neuronal calcium sensor 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NCS1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:10,556,250...10,602,672
Ensembl chr 3:10,553,589...10,602,672
|
|
G |
Ndrg4 |
NDRG family member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NDRG4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:9,766,439...9,802,396
Ensembl chr19:9,766,439...9,801,942
|
|
G |
Nefh |
neurofilament heavy |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NEFH mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:85,181,572...85,191,557
Ensembl chr14:85,181,572...85,191,557
|
|
G |
Nefl |
neurofilament light |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NEFL mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:44,799,378...44,803,251
Ensembl chr15:44,799,334...44,804,574
|
|
G |
Nell1 |
neural EGFL like 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NELL1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:105,348,577...106,218,970
Ensembl chr 1:105,349,069...106,218,958
|
|
G |
Ngfr |
nerve growth factor receptor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NGFR mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:83,389,828...83,408,061
Ensembl chr10:83,389,847...83,408,061
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
diisobutyl phthalate results in increased activity of NR1I2 protein alternative form |
CTD |
PMID:21227907 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions increases activity affects binding |
ISO |
[diisobutyl phthalate co-treated with Androstanols] results in increased activity of NR1I3 protein alternative form diisobutyl phthalate results in increased activity of NR1I3 protein alternative form diisobutyl phthalate binds to NR1I3 protein |
CTD |
PMID:21227907 PMID:25938866 |
|
NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
|
|
G |
Nrxn2 |
neurexin 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NRXN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:221,792,191...221,908,047
Ensembl chr 1:221,792,221...221,908,049
|
|
G |
Nsg1 |
neuronal vesicle trafficking associated 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NSG1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:77,380,264...77,402,007
Ensembl chr14:77,380,262...77,401,996
|
|
G |
Nsg2 |
neuronal vesicle trafficking associated 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NSG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:15,867,885...15,928,169
Ensembl chr10:15,867,887...15,928,169
|
|
G |
Olfm1 |
olfactomedin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of OLFM1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:6,761,031...6,798,739
Ensembl chr 3:6,773,813...6,798,737
|
|
G |
Pcp4 |
Purkinje cell protein 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PCP4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:36,851,035...36,912,272
Ensembl chr11:36,851,038...36,912,229
|
|
G |
Plppr3 |
phospholipid phosphatase related 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PLPPR3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:12,652,555...12,663,825
Ensembl chr 7:12,652,415...12,663,819
|
|
G |
Pls1 |
plastin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PLS1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:103,557,361...103,659,625
Ensembl chr 8:103,557,364...103,608,913
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PPARA mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression increases activity |
ISO |
diisobutyl phthalate binds to and results in increased activity of PPARG protein diisobutyl phthalate results in increased expression of PPARG protein diisobutyl phthalate results in increased activity of PPARG protein |
CTD |
PMID:24155963 PMID:26172262 PMID:27633901 PMID:29061543 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppp2r2b |
protein phosphatase 2, regulatory subunit B, beta |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PPP2R2B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:36,985,709...37,421,383
Ensembl chr18:36,985,714...37,245,809
|
|
G |
Prima1 |
proline rich membrane anchor 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PRIMA1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:127,075,954...127,127,985
Ensembl chr 6:127,075,954...127,127,413
|
|
G |
Prph |
peripherin |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PRPH mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:140,742,406...140,746,197
Ensembl chr 7:140,742,418...140,746,197
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTGES mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:9,727,408...9,738,752
Ensembl chr 3:9,727,408...9,738,752
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTGR1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:76,110,746...76,129,361
Ensembl chr 5:76,110,738...76,129,441
|
|
G |
Ptprn |
protein tyrosine phosphatase, receptor type, N |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTPRN mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:82,446,626...82,462,314
Ensembl chr 9:82,446,633...82,461,903
|
|
G |
Qsox1 |
quiescin sulfhydryl oxidase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of QSOX1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:73,423,396...73,460,890
Ensembl chr13:73,423,397...73,460,935
|
|
G |
Rab3b |
RAB3B, member RAS oncogene family |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB3B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:128,501,789...128,568,170
Ensembl chr 5:128,501,847...128,568,188
|
|
G |
Rab6b |
RAB6B, member RAS oncogene family |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB6B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:111,600,375...111,668,817
Ensembl chr 8:111,600,532...111,668,808
|
|
G |
Rassf4 |
Ras association domain family member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RASSF4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:148,769,092...148,804,295
Ensembl chr 4:148,769,096...148,803,988
|
|
G |
Resp18 |
regulated endocrine-specific protein 18 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RESP18 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:82,470,794...82,477,136
Ensembl chr 9:82,470,759...82,477,181
|
|
G |
Rnf183 |
ring finger protein 183 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of RNF183 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:78,283,722...78,292,729
Ensembl chr 5:78,284,879...78,285,451
|
|
G |
Rtn1 |
reticulon 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RTN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:94,951,016...95,177,477
Ensembl chr 6:94,951,020...95,061,174
|
|
G |
Rtn4r |
reticulon 4 receptor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RTN4R mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:86,992,665...87,017,091
Ensembl chr11:86,992,399...87,017,115
|
|
G |
Rxrg |
retinoid X receptor gamma |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of RXRG mRNA |
CTD |
PMID:22112501 |
|
NCBI chr13:85,818,473...85,868,555
Ensembl chr13:85,818,427...85,868,552
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of SCARB1 mRNA |
CTD |
PMID:22112501 PMID:28655647 |
|
NCBI chr12:36,694,952...36,761,445
Ensembl chr12:36,694,960...36,761,455
|
|
G |
Scg3 |
secretogranin III |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCG3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:82,582,352...82,641,536
Ensembl chr 8:82,582,352...82,641,536
|
|
G |
Scn3b |
sodium voltage-gated channel beta subunit 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCN3B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:44,136,413...44,159,011
Ensembl chr 8:44,136,496...44,159,010
|
|
G |
Scrn1 |
secernin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCRN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:84,678,978...84,740,701
Ensembl chr 4:84,678,975...84,740,909
|
|
G |
Sh3gl3 |
SH3 domain containing GRB2 like 3, endophilin A3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SH3GL3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:144,069,641...144,200,402
Ensembl chr 1:144,069,638...144,200,397
|
|
G |
Sh3tc2 |
SH3 domain and tetratricopeptide repeats 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SH3TC2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:57,286,266...57,403,926
Ensembl chr18:57,286,322...57,347,577
|
|
G |
Shc2 |
SHC adaptor protein 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SHC2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:12,948,952...12,971,174
Ensembl chr 7:12,948,952...12,971,174
|
|
G |
Slc13a2 |
solute carrier family 13 member 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC13A2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:65,664,665...65,692,046
Ensembl chr10:65,664,667...65,692,023
|
|
G |
Slc29a4 |
solute carrier family 29 member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC29A4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr12:13,914,114...13,924,511
Ensembl chr12:13,914,114...13,924,531
|
|
G |
Slc5a7 |
solute carrier family 5 member 7 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC5A7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:5,294,377...5,330,822
Ensembl chr 9:5,294,381...5,330,815
|
|
G |
Smim24 |
small integral membrane protein 24 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SMIM24 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:11,182,975...11,187,222
Ensembl chr 7:11,183,570...11,186,130
|
|
G |
Snhg11 |
small nucleolar RNA host gene 11 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SNHG11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:154,862,717...154,870,691
Ensembl chr 3:154,863,072...154,869,460
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SOD1 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
increases expression |
EXP |
diisobutyl phthalate results in increased expression of SOX9 mRNA |
CTD |
PMID:22112501 |
|
NCBI chr10:101,288,528...101,294,030
Ensembl chr10:101,288,489...101,293,379
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression multiple interactions |
EXP ISO |
diisobutyl phthalate results in decreased expression of STAR mRNA; diisobutyl phthalate results in decreased expression of STAR protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STAR mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of STAR mRNA |
CTD |
PMID:16458459 PMID:21633115 PMID:22112501 PMID:28013214 PMID:28655647 PMID:30802670 |
|
NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847
|
|
G |
Stk32c |
serine/threonine kinase 32C |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STK32C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:211,440,335...211,520,699
Ensembl chr 1:211,440,335...211,520,699
|
|
G |
Stmn4 |
stathmin 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STMN4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:43,007,901...43,025,852
Ensembl chr15:43,007,908...43,025,852
|
|
G |
Syt11 |
synaptotagmin 11 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SYT11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:188,112,301...188,138,180
Ensembl chr 2:188,112,286...188,138,177
|
|
G |
Syt5 |
synaptotagmin 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SYT5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:72,859,806...72,867,934
Ensembl chr 1:72,860,218...72,867,930
|
|
G |
Tbx2 |
T-box transcription factor 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TBX2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:73,278,932...73,290,764
Ensembl chr10:73,279,119...73,289,921
|
|
G |
Tcf23 |
transcription factor 23 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TCF23 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:26,763,159...26,772,074
Ensembl chr 6:26,762,761...26,771,164
|
|
G |
Tcte1 |
t-complex-associated testis expressed 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TCTE1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:17,847,866...17,867,276
Ensembl chr 9:17,846,364...17,866,927
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
diisobutyl phthalate binds to and results in decreased activity of THRB protein |
CTD |
PMID:27633901 |
|
NCBI chr15:8,890,578...9,239,815
Ensembl chr15:8,890,578...9,086,282
|
|
G |
Tmeff2 |
transmembrane protein with EGF-like and two follistatin-like domains 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEFF2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:55,379,130...55,673,704
Ensembl chr 9:55,384,100...55,673,829
|
|
G |
Tmem130 |
transmembrane protein 130 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM130 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr12:11,814,071...11,840,100
Ensembl chr12:11,814,071...11,840,100
|
|
G |
Tmem35a |
transmembrane protein 35A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM35A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:105,134,498...105,145,346
Ensembl chr X:105,134,498...105,145,345
|
|
G |
Tmem63c |
transmembrane protein 63c |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM63C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:111,044,099...111,120,659
Ensembl chr 6:111,049,559...111,120,799
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TRPC6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:6,811,543...6,917,534
Ensembl chr 8:6,811,543...6,917,535
|
|
G |
Ttyh1 |
tweety family member 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TTYH1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:73,734,614...73,753,157
Ensembl chr 1:73,734,624...73,753,128
|
|
G |
Tubb2b |
tubulin, beta 2B class IIb |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB2B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:31,441,640...31,444,687
Ensembl chr17:31,441,630...31,482,759
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:56,220,759...56,229,813
Ensembl chr19:56,220,755...56,229,813
|
|
G |
Tubb4a |
tubulin, beta 4A class IVa |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB4A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:9,961,020...9,968,420
Ensembl chr 9:9,961,021...9,968,486
|
|
G |
Ubash3b |
ubiquitin associated and SH3 domain containing, B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of UBASH3B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:45,224,053...45,375,450
Ensembl chr 8:45,223,992...45,375,435
|
|
G |
Ubxn11 |
UBX domain protein 11 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of UBXN11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:152,332,993...152,356,647
Ensembl chr 5:152,333,043...152,356,890
|
|
G |
Wnt6 |
Wnt family member 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WNT6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:82,033,543...82,047,172
Ensembl chr 9:82,033,543...82,047,166
|
|
G |
Wnt9b |
Wnt family member 9B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WNT9B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:91,785,892...91,808,061
Ensembl chr10:91,785,893...91,807,937
|
|
G |
Wt1 |
WT1 transcription factor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WT1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:95,133,221...95,180,574
Ensembl chr 3:95,133,713...95,180,564
|
|
G |
Zcchc12 |
zinc finger CCHC-type containing 12 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ZCCHC12 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:122,808,581...122,811,790
Ensembl chr X:122,808,605...122,811,789
|
|
G |
Zfat |
zinc finger and AT hook domain containing |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of ZFAT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:109,037,777...109,207,511
Ensembl chr 7:109,037,845...109,205,354
|
|
G |
Zp2 |
zona pellucida glycoprotein 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ZP2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:189,899,906...189,911,650
Ensembl chr 1:189,899,892...189,911,650
|
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
increases expression |
ISO |
isobutyl nitrite results in increased expression of FGF1 mRNA |
CTD |
PMID:16288974 |
|
NCBI chr18:32,273,830...32,359,831
Ensembl chr18:32,273,770...32,359,824
|
|
G |
Fgf4 |
fibroblast growth factor 4 |
increases expression |
ISO |
isobutyl nitrite results in increased expression of FGF4 mRNA |
CTD |
PMID:16288974 |
|
NCBI chr 1:218,024,537...218,029,539
Ensembl chr 1:218,025,810...218,027,220
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
isobutyl nitrite results in increased expression of HMOX1 mRNA |
CTD |
PMID:16288974 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hspa4 |
heat shock protein family A (Hsp70) member 4 |
increases expression |
ISO |
isobutyl nitrite results in increased expression of HSPA4 mRNA |
CTD |
PMID:16288974 |
|
NCBI chr10:38,601,624...38,642,397
Ensembl chr10:38,601,624...38,642,397
|
|
G |
Pf4 |
platelet factor 4 |
increases expression |
ISO |
isobutyl nitrite results in increased expression of PF4 mRNA |
CTD |
PMID:16288974 |
|
NCBI chr14:18,848,549...18,849,258
Ensembl chr14:18,848,549...18,849,258
|
|
G |
Smad7 |
SMAD family member 7 |
increases expression |
ISO |
isobutyl nitrite results in increased expression of SMAD7 mRNA |
CTD |
PMID:16288974 |
|
NCBI chr18:71,395,830...71,424,164
Ensembl chr18:71,395,830...71,424,157
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
isobutyl nitrite results in increased expression of VEGFA mRNA |
CTD |
PMID:16288974 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vegfd |
vascular endothelial growth factor D |
increases expression |
ISO |
isobutyl nitrite results in increased expression of VEGFD mRNA |
CTD |
PMID:16288974 |
|
NCBI chr X:31,816,480...31,852,239
Ensembl chr X:31,816,436...31,851,715
|
|